COVID-19 vaccination safety in individuals with immune-mediated neuropathy


  • SARS-CoV-2 vaccination is not associated with increased risk of Guillain-Barré syndrome (GBS) recurrence but is associated with a transient increased risk of mild symptom exacerbation for individuals with chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN).

Why this matters?

  • Vaccination is a source of worry for individuals with a history of immune-mediated neuropathy due to potential recurrence of GBS, or exacerbation of CIDP or MMN.

  • Individuals with GBS, CIPD, or MMN were excluded from initial SARS-CoV-2 vaccine trials but data on safety and efficacy is imperative for optimal risk management and treatment for this population.